Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-26T20:22:05.578Z Has data issue: false hasContentIssue false
  • English
  • Français

The cost-effectiveness of Ixel®, A new SNRI, in comparison with a panel of TCAs and SSRIs, in the treatment of depression

Published online by Cambridge University Press:  16 April 2020

G. Berdeaux ,
R. Dardennes ,
A. Lafuma  and
F. Fagnani
G. Berdeaux
Affiliation:
Pierre Fabre Médicament, Boulogne-Billancourt
R. Dardennes
Affiliation:
Hôpital Saint-Anne, Paris
A. Lafuma
Affiliation:
Cemka, Bourg-la-Reine, France
F. Fagnani
Affiliation:
Cemka, Bourg-la-Reine, France

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Symposia
Information
European Psychiatry , Volume 13 , Issue S4: Standards of psychiatry - 9th Congress of Association of European Psychiatrists , 1998 , pp. 263s
Copyright
Copyright © European Psychiatric Association 1998
Submit a response

Comments

No Comments have been published for this article.